We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Leptospirosis Test Could Improve Treatment Options

By LabMedica International staff writers
Posted on 02 Oct 2025

Leptospirosis is a tropical disease that affects about 1 million people each year, causing nearly 60,000 fatalities worldwide. More...

It spreads through contact with the urine of infected animals and can lead to severe illness, including jaundice, kidney injury, and pulmonary hemorrhage if not treated promptly. However, diagnosis has long been difficult due to the lack of sensitive and specific tests. A new diagnostic method now offers a promising way to identify the disease earlier.

Researchers at the Yale School of Medicine (YSM, New Haven, CT, USA) and Luna Bioscience (Groton, CT, USA) have developed a monoclonal antibody (mAb)-based capture immunoassay that targets virulence-modifying (VM) proteins. These proteins are a recently identified family of leptospiral exotoxins crucial to the disease’s pathogenesis. The new test detects these proteins in blood and urine samples, enabling the identification of infections much earlier than current methods.

The team evaluated their approach using hamster models of leptospirosis. By detecting VM proteins circulating in the blood and urine, the assay successfully confirmed infection with high specificity. Their findings, published in Microbiology Spectrum, mark the first time leptospirosis has been identified as a systemic bacterial disease mediated by a toxin, comparable to tetanus or diphtheria, with potential for rapid antigen detection.

This breakthrough lays the foundation for developing inexpensive, easy-to-use diagnostics that could be deployed in resource-limited settings where the disease is most prevalent. Early detection would enable clinicians to begin treatment sooner, reducing fatalities and preventing complications. In addition to diagnosis, identifying VM proteins as central to the disease may also unlock new opportunities for therapeutic drug design and vaccine development.

“By enabling early detection, health care providers can initiate timely treatments, potentially saving lives and mitigating disease severity. Furthermore, understanding the role of VM proteins in disease pathogenesis could lead to new therapeutic targets and vaccine development opportunities,” said Dr. Joseph M. Vinetz, professor of medicine (infectious diseases) at Yale School of Medicine and senior author of the study.

Related Links:
YSM 


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.